EP2866830A4 - Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation - Google Patents

Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation

Info

Publication number
EP2866830A4
EP2866830A4 EP12880044.8A EP12880044A EP2866830A4 EP 2866830 A4 EP2866830 A4 EP 2866830A4 EP 12880044 A EP12880044 A EP 12880044A EP 2866830 A4 EP2866830 A4 EP 2866830A4
Authority
EP
European Patent Office
Prior art keywords
anti
cxcl11
cxcl13
cxcl9
cxcr5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP12880044.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2866830A1 (en
Inventor
James W Lillard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JYANT TECHNOLOGIES
Original Assignee
JYANT TECHNOLOGIES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JYANT TECHNOLOGIES filed Critical JYANT TECHNOLOGIES
Priority to PCT/US2012/044464 priority Critical patent/WO2014003742A1/en
Publication of EP2866830A1 publication Critical patent/EP2866830A1/en
Publication of EP2866830A4 publication Critical patent/EP2866830A4/en
Application status is Pending legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
EP12880044.8A 2012-06-27 2012-06-27 Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation Pending EP2866830A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2012/044464 WO2014003742A1 (en) 2012-06-27 2012-06-27 Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation

Publications (2)

Publication Number Publication Date
EP2866830A1 EP2866830A1 (en) 2015-05-06
EP2866830A4 true EP2866830A4 (en) 2015-12-09

Family

ID=49783685

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12880044.8A Pending EP2866830A4 (en) 2012-06-27 2012-06-27 Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation

Country Status (5)

Country Link
EP (1) EP2866830A4 (ja)
JP (1) JP2015524793A (ja)
CN (1) CN104870013A (ja)
HK (1) HK1212628A1 (ja)
WO (1) WO2014003742A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459971A (zh) * 2014-04-08 2017-02-22 弗劳恩霍夫应用研究促进协会 用于治疗自身免疫性疾病的联合疗法
CN105039319A (zh) * 2015-06-22 2015-11-11 浙江理工大学 用于预测乳腺癌新辅助化疗疗效的生物标记物和荧光定量免疫pcr试剂盒
AU2017281830A1 (en) 2016-06-20 2018-12-13 Kymab Limited Anti-PD-L1 antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
WO2012082494A2 (en) * 2010-12-14 2012-06-21 Morehouse School Of Medicine The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT360689T (de) * 1996-09-10 2007-05-15 Kocher Theodor Inst Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung
MX2010001975A (es) * 2007-08-29 2010-03-10 Sanofi Aventis Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso.
NZ608318A (en) * 2010-09-02 2015-03-27 Vaccinex Inc Anti-cxcl13 antibodies and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
WO2012082494A2 (en) * 2010-12-14 2012-06-21 Morehouse School Of Medicine The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2005 (2005-03-01), GLABINSKI ANDRZEJ ET AL: "Modulation of brain immune-mediated inflammation with anti-chemokine antibodies", XP002747239, Database accession no. PREV200510320434 *
FASEB JOURNAL, vol. 19, no. 5, Suppl. S, Part 2, March 2005 (2005-03-01), EXPERIMENTAL BIOLOGY 2005 MEETING/35TH INTERNATIONAL CONGRESS OF PHYSIOLOGICAL SCIENCES; SAN DIEGO, CA, USA; MARCH 31 -APRIL 06, 2005, pages A1443, ISSN: 0892-6638 *
FLIER J ET AL: "Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation", JOURNAL OF PATHOLOGY, JOHN WILEY & SONS LTD, GB, vol. 194, no. 4, 1 August 2001 (2001-08-01), pages 398 - 405, XP002432876, ISSN: 0022-3417, DOI: 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S *
JENNY L. HARDISON ET AL.: "The chemokines CXCL9 and CXCL10 promote a protective immune response but do not contribute to cardiac inflammation following infection with Trypanosoma cruzi", INFECTION AND IMMUNITY, vol. 74, no. 1, January 2006 (2006-01-01), pages 125 - 134, XP002747240 *
RUSCHPLER PETER ET AL: "High CXCR3 expression in synovial mast cells associated with CXCL9 and CXCL10 expression in inflammatory synovial tissues of patients with rheumatoid arthritis", ARTHRITIS RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 5, no. 5, 26 June 2003 (2003-06-26), pages R241 - R252, XP021011812, ISSN: 1465-9905, DOI: 10.1186/AR783 *
See also references of WO2014003742A1 *

Also Published As

Publication number Publication date
EP2866830A1 (en) 2015-05-06
CN104870013A (zh) 2015-08-26
WO2014003742A1 (en) 2014-01-03
HK1212628A1 (zh) 2016-06-17
JP2015524793A (ja) 2015-08-27

Similar Documents

Publication Publication Date Title
GB2508520B (en) Methods and devices for compound delivery
TWI543980B (en) Heterocyclylamines as pi3k inhibitors
SI2935222T1 (sl) Inhibitorji PRMT5 in njihove uporabe
TWI589579B (en) Irak inhibitors and uses thereof
EP2723384A4 (en) Treatment of proteinopathies
EP2678018A4 (en) Combination of kanase inhibitors and uses thereof
EP2887805A4 (en) Compounds and methods for treatment of hypertension
EP2911669A4 (en) Synergistic combination of immunologic inhibitors for the treatment of cancer
EP2675469A4 (en) Compositions, devices and methods of use thereof for the treatment of cancers
HK1220027A1 (zh) 欺詐的有效預防
HK1199255A1 (en) Indazole compounds, compositions and methods of use
HK1210957A1 (en) Effluz inhibitor compositions and methods of treatment using the same
HK1210696A1 (zh) 抑制劑及其用途
IL234989A (en) Compounds and compositions thereof for treating cancer
HK1207861A1 (en) Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1
EP2890678A4 (en) Glycosidase inhibitors and uses thereof
IL238958D0 (en) Glutamase inhibitors, compositions comprising same and uses thereof
EP2665483A4 (en) Topical minocycline compositions and methods of using the same
EP2670434A4 (en) Treatment of tauopathies
TWI548621B (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
EP2736528A4 (en) Compositions and methods for the treatment of hiv
GB2508204B (en) Orthosis
EP2920149A4 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EP2681200A4 (en) Benzimidazole inhibitors of the sodium channel
EP2694485A4 (en) Combinations of akt inhibitor compounds and vemurafenib, and methods of use

Legal Events

Date Code Title Description
17P Request for examination filed

Effective date: 20141211

AK Designated contracting states:

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent to

Extension state: BA ME

DAX Request for extension of the european patent (to any country) deleted
RIC1 Classification (correction)

Ipc: A61K 48/00 20060101ALI20151023BHEP

Ipc: A61P 29/00 20060101ALI20151023BHEP

Ipc: A61K 39/395 20060101AFI20151023BHEP

RA4 Despatch of supplementary search report

Effective date: 20151106

17Q First examination report

Effective date: 20170406

18D Deemed to be withdrawn

Effective date: 20170817

18RA Date of receipt of request for re-establishment of rights

Effective date: 20180626

D18D Ep-application deemed to be withdrawn: (deleted)